This study retrospectively analyzed the registered data of patients with HER2-low BC who were treated with NAC This is the first study to comprehensively assess the roles of clinicopathological characteristics, hematologic markers, NLR, PLR, LMR and SII in predicting axillary pCR in patients with HER2-low BC treated with NAC. This evidence concerns the gene ERBB2 and breast cancer.